The Recall Desk
ModerateFDA (Drugs)·D-0298-2026·Announced 2026-02-04

Antacid tablets recalled after failing disintegration time specifications

Sato Pharmaceutical is recalling 3,640 bottles of INON ACE Antacid tablets after the lot failed disintegration specifications, taking longer than expected.

What this means for you

Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.

Our severity reasoning: Scored 2 because the record cites a failed disintegration specification with no stated clinical consequence or reported harm.

Plain-English summary

INON ACE Antacid tablets, containing magnesium aluminosilicate, magnesium hydroxide and simethicone, in 75-count bottles under NDC 49873-402-01, are being recalled by Sato Pharmaceutical Co., Ltd.

The reason given in the enforcement record is failed disintegration specifications: above the time expected.

The record lists 3,640 bottles from lot PWXT, expiry 1/31/2027. Distribution was to California and Hawaii. The FDA has classified the action as Class II.

The record cites an out-of-specification disintegration time and names no clinical consequence. Consumers should follow the retailer's return instructions.

The recalled product

Product
INON ACE (MAGNESIUM ALUMINOSILICATES, MAGNESIUM HYDROXIDE, SIMETHICONE)
Brand
INON ACE
Affected units
3,640

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (2)

  • Lot#: PWXT
  • Exp 1/31/2027

UPCs (1)

  • 0349873402017

Distribution

Distributed in 2 states: